

Evaluation of Electrolyte Management in Patients Receiving Diuretics

Gudipati Lokesh, Kuruba Kavya, Alluri Akshaya, Katravath Hari Krishna Naik
Department of Pharmacy Practice, Santhiram College of Pharmacy, Nandyal-518112, Andhra Pradesh-INDIA.

Date of Submission: 20-09-2025

Date of Acceptance: 30-09-2025

ABSTRACT

Background: Diuretics are globally applied in the management of hypertension, heart failure, and chronic kidney disease. Though they are effective, their administration is usually complicated by electrolyte disturbances, which in turn lead to significant clinical implications. Their monitoring by pharmacists helps to avoid such risks.

Objective: To evaluate the influence of diuretic treatment on the electrolytes and emphasize the role of pharmacists in optimizing electrolyte therapy.

Methods: A prospective observational study was conducted in 150 diuretic patients. Demographic data, diuretic type prescribed, and baseline and follow-up electrolyte levels (sodium, potassium, calcium, and magnesium) were recorded and compared. Patients were categorized based on diuretic type furosemide, hydrochlorothiazide (HCTZ), or spironolactone and electrolyte imbalance was quantified correspondingly.

Results: Out of 150 patients, most were from the age group 40–60 years with a nearly equal sex distribution. Furosemide was most frequently prescribed diuretic (64.7%), followed by HCTZ (21.3%) and spironolactone (14%). Furosemide and HCTZ were both linked with notable decreases in sodium (average reduction 3–6 mmol/L) and potassium (average reduction 1–1.5 mmol/L), where hypokalemia was most common disturbance. Hypomagnesemia and mild hypocalcemia were also seen, mostly with loop diuretics. Spironolactone significantly maintained potassium levels, although small reductions in calcium and magnesium were present.

Conclusion: Electrolyte imbalances, especially hyponatremia and hypokalemia, are prevalent in diuretic consumers. Regular monitoring, early supplementation, and pharmacist interventions are vital in averting complications, enhancing therapeutic response, and promoting patient safety.

Key words: Diuretics, Electrolyte Imbalance, Hypokalemia, Hyponatremia, Hypomagnesemia, Hypocalcaemia, Electrolyte Monitoring, Pharmacist Intervention, Patient Outcomes.

I. INTRODUCTION

Diuretics are regularly applied in clinical management of cardiovascular and renal illnesses such as hypertension, congestive heart disease and chronic kidney disease. The drugs play a critical role in the control of blood pressure, mitigation of fluid overload, and symptomatic improvement in the afflicted patients by enhancing the renal excretion of sodium and water (Cuthbert, J. J., & Clark, A. L. 2024). While they are of advantage, diuretics are commonly seen with electrolyte disturbances. These disturbances in the form of hyponatremia, hypokalemia, hypocalcemia and hypomagnesemia are common and are responsible for serious clinical sequelae like cardiac arrhythmias, neuromuscular pathology, acute kidney injury, and aggravate total patient morbidity and mortality. If left undiagnosed or inadequately addressed, these complications can lead to prolonged hospitalization and higher healthcare costs (Blebea, N., 2025).

Several studies have demonstrated that the prevalence of electrolyte disturbances in diuretic users is high, especially among elderly patients with multiple comorbidities. Thiazides induce hyponatremia frequently, whereas loop diuretics such as furosemide induce hypokalemia and hypomagnesemia substantially. Potassium-sparing diuretics; since they may lower the risk of hypokalemia, do not eliminate potassium which they may induce hyperkalemia in certain individuals, most notably those with renal insufficiency (Andersson, N. W., 2023) (Wu, L., Rodriguez, M., 2024). Therefore, the choice of diuretic and patient factors both directly and interactively incur the risk and severity of such electrolyte abnormalities. Clinical practice guidelines emphasize baseline assessment and serial monitoring of serum electrolytes, especially in long-term treatment. However, adherence to these in everyday practice is poor with avoidable complications resulting as a direct consequence (Nyma, Z, et.al., 2024).

Pharmacists, as members of the multidisciplinary healthcare team, have a critical role in maximizing medication safety and therapeutic outcomes. Their role goes beyond dispensing drugs to include active drug therapy monitoring, identifying potential drug-related problems, patient counseling, and interaction with physicians to suggest timely interventions (Alam, K, et.al., 2024). Evidence indicates that pharmacist-led interventions like medication reviews, recommendations for supplementation, and dietary and adherence counseling can contribute substantially to patient outcomes by reducing the rate of dangerous electrolyte disorders. Furthermore, organized pharmacist input improves adherence to guideline-directed monitoring guidelines and overall care quality (Alshogran, O. Y, et.al., 2022).

In light of this, the assessment of diuretic therapy patients electrolyte management practice is timely and imperative. This research will seek to identify the prevalence of electrolyte disturbances among diuretic-treated patients, measure the effectiveness of existing monitoring and supplementation practices, and explore the role of pharmacist intervention in maximizing therapeutic outcome (Chirnside, J. G, et.al., 2024). Conclusions of the research will give information about gaps in practice present now and will emphasize the significance of systematic monitoring and intervention by pharmacists for enhancing patient safety and clinical outcomes.

Against this backdrop, it is important to have systematic assessments of the efficacy of electrolyte management methods among patients on diuretics. The purpose of this study is to assess the efficacy of strategies for managing electrolytes in patients on diuretic therapy and the study encompasses the different objectives to ascertain the incidence of electrolyte imbalances among patients on diuretics, to compare the efficacy of strategies for monitoring and supplementing electrolytes to prevent and correct imbalances, to examine the effects of electrolyte imbalance on patient outcomes, such as hospital stay, morbidity, and mortality and to compare the contribution of pharmacists to ensuring optimal electrolyte management among patients on diuretics.

II. MATERIALS AND METHODS

This was a prospective observational study conducted over a period of six months in a tertiary care hospital. The study was designed to evaluate the effectiveness of electrolyte management

strategies in patients receiving diuretic therapy by comparing baseline values with follow-up values after treatment.

Study Population and Eligibility

A total of 150 patients were planned to be enrolled during the study period. Patients aged 18 years and above who were prescribed diuretics such as furosemide, hydrochlorothiazide, or spironolactone for conditions including hypertension, heart failure, or chronic kidney disease were considered eligible. Patients with pre-existing severe electrolyte imbalances at baseline, those undergoing dialysis, or those with contraindications to diuretic therapy were excluded.

Data Collection

Data were collected prospectively from patient records, laboratory reports, and direct follow-up during therapy. The following parameters were documented:

- **Demographics:** Age, gender, medical history, and indication for diuretic therapy.
- **Diuretic Therapy Details:** Type of diuretic prescribed, dosage, frequency, and duration of therapy.
- **Electrolyte Monitoring:** Baseline and follow-up levels of sodium, potassium, calcium, magnesium, and chloride measured at regular intervals during therapy.
- **Management Strategies:** Frequency of monitoring, use of supplementation (e.g., potassium or magnesium), and modifications in diuretic regimen based on clinical response.
- **Clinical Outcomes:** Incidence of electrolyte imbalances such as hyponatremia and hypokalemia, associated symptoms, interventions required (e.g., intravenous correction, hospitalization), and patient outcomes including hospitalization duration, morbidity, and mortality.

Role of Pharmacist

The role of the pharmacist was evaluated in terms of monitoring electrolyte levels, identifying potential imbalances, recommending supplementation or adjustments in diuretic therapy, and educating both healthcare providers and patients on the importance of regular electrolyte monitoring. Pharmacist-led interventions were compared against standard care practices to assess their impact on prevention and correction of electrolyte disturbances.

Statistical Analysis

Descriptive statistics were used to summarize patient demographics, diuretic therapy patterns, and incidence of electrolyte imbalances. Continuous variables such as electrolyte levels before and after therapy were compared using paired t-tests. Categorical variables were analyzed using chi-square tests. Statistical analysis was performed using standard statistical software, with a p-value <0.05 considered statistically significant.

Ethical Considerations

The study protocol was reviewed and approved by the Institutional Ethics Committee of the hospital. Informed consent was obtained from all participants prior to enrollment. Patient confidentiality was strictly maintained, and all data were anonymized for analysis.

III. RESULTS

There were 150 patients under study that were above 18 years old and put on diuretic drugs for hypertension, heart failure, or chronic kidney

disease. Patients with extreme baseline electrolyte imbalances, dialysis, and contraindications to diuretic therapy had to be excluded. Age distribution in the study population showed the highest number of patients between ages 40 and 50, forming 28% of the total cases (42 patients: 23 furosemide, 13 hydrochlorothiazide, and 6 spironolactone). Next came those in the 51-60 age range, constituting 24% of the sample (36 patients: 22 furosemide, 5 hydrochlorothiazide, and 9 spironolactone). The age groups 61-70 and 71-80 recorded equal numbers of cases, 20.7% (31 patients), bidirectionally divided among the medicines. However, the least representation was given to the 81-90 group with merely 10 cases (seven furosemide, two hydrochlorothiazide, and one spironolactone), or just 6.6% of the total sample. This distribution highlights that the majority of patients were middle-aged and elderly, consistent with the higher prevalence of hypertension, heart failure, and chronic kidney disease in these age brackets (Table 1 and Figure 1).

Table 1: Age distribution among patients

AGE RANGE (years)	FUROSEMIDE	HCTZ	SPIRONOLACTONE	TOTAL CASES
40-50	23	13	6	42
51-60	22	5	9	36
61-70	23	6	2	31
71-80	22	6	3	31
81-90	7	2	1	10
TOTAL	97	32	21	150




Figure 1: Age distribution among patients

Gender-wise distribution showed a nearly balanced pattern, with 71 males and 79 females included in the study. Furosemide was the most commonly prescribed diuretic across both genders, with 50 male and 47 female patients receiving the drug. Hydrochlorothiazide was prescribed to 13 males and 19 females, while spironolactone was

administered to 8 males and 13 females. This distribution indicates a slightly higher representation of females (52.7%) compared to males (47.3%), thereby supporting the internal validity of gender comparisons (Table 2 and Figure 2).

Table 2: Gender-wise distribution of patients prescribed diuretic drugs

DIURETIC DRUG	MALE	FEMALE	TOTAL
FUROSEMIDE	50	47	97
HCTZ	13	19	32
SPIRONOLACTONE	8	13	21
TOTAL	71	79	150




Figure 2: Gender-wise distribution based on drug

Analysis of the overall distribution of cases by diuretic drug prescribed revealed that furosemide accounted for the highest proportion (64.7%), with 97 out of 150 patients receiving it. Hydrochlorothiazide was prescribed in 32 cases (21.3%), while spironolactone was the least prescribed, with 21 cases (14%). This prescribing trend reflects the broader clinical preference for furosemide as a first-line loop diuretic in managing fluid overload associated with hypertension, heart failure, and renal conditions (Table 3 and Figure 3).

Overall, the study sample demonstrated a balanced gender distribution and wide age coverage, while also indicating the predominance of furosemide use among prescribed diuretic therapies. This structured representation across age, gender, and drug categories strengthens the study's reliability and ensures that clinical outcomes can be interpreted with reduced bias from demographic or treatment-related imbalances.

Table 3: Distribution of cases by diuretic drug prescribed

DIURETIC DRUG	NO. OF CASES
FUROSEMIDE	97
HCTZ	32
SPIRONOLACTONE	21
TOTAL	150




Figure 3: No. of cases for each drug

Table 4: Electrolyte Values Before and After Furosemide Treatment

Patient ID	Na ⁺ Before	Na ⁺ After	K ⁺ Before	K ⁺ After	Ca ²⁺ Before	Ca ²⁺ After	Mg ²⁺ Before	Mg ²⁺ After
1	140.7	136.5	4.5	4	9.4	8.7	2.1	1.7
2	141.8	137.8	4	3.3	9.1	8.5	2.1	1.8
3	138.9	135	4.4	3.5	9.1	8.5	2.1	1.8
4	139.8	137.2	4.4	3.8	9.4	8.9	2	1.7
5	141.4	137.3	4.5	3.8	9.2	8.6	2.1	1.7
6	141.3	136.8	4.3	3.2	9.4	8.8	2.1	1.6
7	141.6	137	4	3.3	9.4	8.6	2.1	1.7
8	140.1	135.4	4.4	3.5	9.3	8.8	2.2	1.9
9	140.8	137.2	4.4	3.6	9.3	8.5	2	1.6
10	138.2	133.7	4.3	3.3	9.4	8.9	2.1	1.6



11	138.6	136.1	4.3	3.5	9.3	8.6	2	1.7
12	138	134.9	4.4	3.5	9.2	8.5	2	1.6
13	138.8	135.1	4.2	3	9.1	8.4	2.2	1.9
14	139.7	136.3	4.4	3.7	9.2	8.8	2.1	1.8
15	140.1	135.5	4.4	3.7	9	8.3	2.2	2
16	141	138.4	4.4	3.4	9.1	8.5	2	1.7
17	141.3	137.1	4.3	3.3	9.5	8.9	2.2	1.8
18	138.4	134.1	4.1	3.5	9.2	8.5	2	1.5
19	140.4	137.8	4.3	3.2	9.3	8.5	2	1.6
20	141.9	137.3	4.1	3.5	9.1	8.7	2	1.7
21	141.6	138	4.2	3.4	9.2	8.4	2	1.7
22	138.1	134.1	4.4	3.7	9.4	8.9	2.2	1.8
23	140.4	137.5	4	2.9	9.3	8.7	2.2	1.7
24	139.5	135	4.2	3.1	9.5	9	2.1	1.7
25	141.8	136.9	4.5	3.9	9.4	8.7	2.1	1.7
26	140.3	136.6	4.2	3.4	9.2	8.6	2	1.8
27	139.9	135.7	4.2	3.6	9	8.3	2	1.7
28	140.5	135.8	4.3	3.7	9.4	8.8	2.1	1.7
29	139.1	134.9	4.2	3	9.4	8.9	2.1	1.8
30	138.8	134.1	4.2	3.3	9.2	8.6	2.2	1.9
31	140	136.1	4.3	3.7	9.3	8.8	2.2	1.8
32	140.5	137.1	4.4	3.2	9.2	8.4	2.2	1.7
33	139.7	135.2	4.5	3.5	9.2	8.4	2.1	1.8
34	138.2	135	4.3	3.2	9.4	8.9	2.1	1.7
35	139.2	134.6	4.3	3.6	9.5	9	2.2	1.9
36	139.9	136.1	4.1	3.4	9.3	8.8	2.1	1.6
37	139.4	135.4	4	2.8	9.1	8.6	2.2	1.8
38	138.1	134.4	4.1	3.3	9.4	8.7	2.2	1.8
39	139.4	134.8	4.4	3.8	9.1	8.7	2.1	1.8
40	139.1	134.5	4	2.8	9.3	8.7	2.1	1.8
41	141.5	138.3	4.1	3.4	9.3	8.7	2.1	1.9
42	139.4	135.3	4.2	3.7	9	8.5	2.1	1.7
43	139.5	135.8	4.1	3.5	9.1	8.4	2.2	1.9
44	139.7	136.3	4.2	3.3	9.1	8.6	2	1.8
45	138.6	134.5	4.3	3.4	9.1	8.3	2.2	1.8
46	139.2	135.7	4.1	3.6	9.4	8.9	2.2	1.8
47	138.9	135.6	4.5	3.4	9.3	8.8	2	1.7
48	138.8	135.4	4.1	3.2	9	8.3	2.1	1.7
49	141.2	137.2	4	2.8	9.3	8.6	2	1.5
50	141	138.5	4.1	3.5	9.4	8.7	2.2	1.7
51	138.7	135.1	4	3.1	9	8.3	2.1	1.7
52	141	137.7	4	3	9.3	8.7	2.2	1.7



53	139.9	135.6	4.3	3.3	9.1	8.5	2.1	1.8
54	141.5	137.3	4.4	3.5	9.3	8.6	2.1	1.7
55	141	138.4	4.3	3.5	9.1	8.5	2.1	1.9
56	140.2	135.6	4.2	3.2	9	8.4	2.1	1.8
57	139.7	136.6	4.4	3.5	9	8.5	2.1	1.7
58	140.6	136.7	4.3	3.7	9	8.5	2.2	1.9
59	140	136.3	4.5	3.9	9.3	8.6	2.1	1.8
60	138	134.4	4.2	3.6	9.3	8.6	2.1	1.7
61	140.6	137.6	4.2	3.3	9.4	8.8	2.1	1.6
62	138.4	133.7	4.1	3.3	9.3	8.9	2	1.8
63	141.9	139.4	4.3	3.2	9.2	8.4	2.1	1.8
64	139.8	136.9	4.2	3.1	9.3	8.6	2	1.7
65	141.6	138.6	4.3	3.6	9.5	9.1	2.2	1.9
66	141.2	136.7	4.4	3.7	9.5	8.9	2.1	1.7
67	139.9	137.2	4.1	3.5	9	8.4	2	1.6
68	141.4	137.7	4	3.2	9	8.4	2	1.5
69	138.4	133.8	4.3	3.6	9.3	8.6	2.1	1.9
70	138.3	133.7	4.2	3.2	9.3	8.7	2.2	1.7
71	139	135	4.4	3.4	9	8.4	2	1.6
72	138.3	133.6	4.2	3.5	9.5	8.9	2.1	1.7
73	140.4	137.8	4.2	3.7	9.2	8.6	2.2	1.9
74	141.2	138.4	4.5	3.5	9.4	8.6	2	1.6
75	140.4	135.7	4.4	3.8	9	8.5	2.2	1.8
76	140.8	137.3	4	3.1	9.3	8.7	2.1	1.8
77	139.8	135.6	4.1	3.5	9	8.3	2.1	1.9
78	138.2	134.4	4.2	3.3	9.1	8.6	2.2	1.9
79	141.9	137.7	4.1	3	9.4	8.9	2.1	1.7
80	138.1	133.4	4.5	3.5	9	8.3	2.2	1.8
81	138.5	135	4.5	3.3	9.4	9	2	1.6
82	141.2	136.6	4.2	3.2	9.2	8.8	2.1	1.8
83	140.4	137.5	4.3	3.5	9.1	8.4	2.1	1.8
84	138.6	135.3	4.2	3.5	9.5	9.1	2.1	1.6
85	140.9	136.7	4.2	3.7	9.3	8.5	2.1	1.6
86	141	137.3	4.1	3.4	9.2	8.6	2.1	1.8
87	139.2	135.6	4.2	3.5	9.2	8.7	2	1.8
88	141.1	138.2	4.4	3.5	9.1	8.7	2.1	1.6
89	140.7	137.7	4	2.8	9.4	8.6	2.1	1.7
90	140.2	136.9	4.5	3.4	9.5	8.7	2	1.7
91	141.8	137.5	4.4	3.8	9.3	8.8	2.1	1.6
92	138.5	134.5	4.4	3.5	9.4	8.8	2.2	1.9
93	141.8	137.2	4.5	3.3	9	8.3	2.2	1.8
94	141	136.2	4.4	3.9	9.5	9	2.1	1.7

95	141.8	138.1	4	3.3	9.2	8.6	2.2	1.8
96	140	135.5	4.1	3	9.1	8.5	2.2	1.9
97	141.8	137.3	4.4	3.3	9.2	8.5	2.1	1.8

Table 5: Electrolyte Values Before and After Hydrochlorothiazide Treatment

Patient ID	Na ⁺ Before	Na ⁺ After	K ⁺ Before	K ⁺ After	Ca ²⁺ Before	Ca ²⁺ After	Mg ²⁺ Before	Mg ²⁺ After
1	141.9	137.3	4.4	3.8	9.2	8.8	2.2	1.7
2	140.7	135.8	4	3.1	9.1	8.4	2.1	1.9
3	139.4	134.4	4.1	3.3	9.4	8.9	2	1.7
4	140.9	136.2	4.5	3.6	9.5	9.1	2	1.7
5	141.2	138.3	4.5	3.9	9.3	8.7	2.2	1.8
6	139.4	134.7	4.1	3.3	9.3	8.8	2.1	1.7
7	141.9	139.3	4.2	3.4	9.1	8.6	2.1	1.8
8	140.2	136.4	4.2	3.2	9.2	8.8	2.2	1.7
9	141.5	136.7	4.2	3.6	9.1	8.6	2.1	1.8
10	138.8	135.8	4.2	3.7	9.3	8.8	2.1	1.9
11	138.5	136	4.3	3.6	9	8.6	2.2	1.8
12	141.4	138.6	4.3	3.8	9.4	9	2.1	1.8
13	140.4	137.7	4.1	3.1	9.1	8.4	2.2	1.7
14	140	137	4.2	3.2	9.5	9.1	2.2	1.8
15	139	136	4.4	3.7	9.1	8.5	2	1.8
16	139.9	137.2	4.4	3.2	9.3	8.8	2.1	1.9
17	138.3	133.7	4.4	3.4	9.2	8.8	2	1.8
18	141.8	137.9	4.5	3.4	9.2	8.6	2.2	1.9
19	140.9	135.9	4.3	3.6	9.2	8.8	2	1.7
20	138.4	134.7	4.3	3.2	9.2	8.8	2.2	1.7
21	138.7	135.5	4.2	3.4	9.4	8.9	2	1.7
22	140.5	137.5	4.1	3.6	9.2	8.6	2.2	1.8
23	141.1	137.9	4.3	3.8	9.4	8.7	2	1.5
24	142	137.6	4.1	3.3	9	8.4	2	1.6
25	139.5	136.3	4	3.1	9.4	8.8	2.1	1.8
26	141.7	138.1	4.2	3.1	9.3	8.6	2.2	1.9
27	139	134.1	4.4	3.7	9.1	8.6	2.2	1.8
28	141.6	139	4.3	3.3	9.4	8.8	2	1.8
29	140.4	137.6	4.1	3.4	9	8.3	2.1	1.8
30	140.1	136.4	4.3	3.3	9.1	8.5	2.1	1.9
31	140	135.1	4.4	3.3	9	8.5	2	1.8
32	138.5	135.6	4.4	3.4	9.1	8.4	2.1	1.7

Table 6: Electrolyte Values Before and After Spironolactone Treatment

Patient ID	Na ⁺ Before	Na ⁺ After	K ⁺ Before	K ⁺ After	Ca ²⁺ Before	Ca ²⁺ After	Mg ²⁺ Before	Mg ²⁺ After
1	141	138.1	4.5	3.6	9	8.5	2.1	1.6
2	139.6	135.8	4.2	3.6	9.3	8.6	2.1	1.9
3	139.3	135.7	4.1	3.3	9.1	8.5	2.1	1.8
4	141	136.4	4.1	3.5	9.3	8.6	2.1	1.8
5	139.9	135.6	4.1	3.2	9.1	8.4	2.2	2
6	139.5	135.7	4.5	3.6	9.2	8.6	2	1.6
7	141.2	138.1	4	3.2	9.1	8.5	2.2	1.8
8	138.6	135.7	4.3	3.4	9.1	8.5	2.2	2
9	141.3	138.4	4.3	3.8	9.3	8.5	2.1	1.7
10	140.9	136.2	4.1	3.5	9.3	8.6	2.2	1.7
11	138.1	135	4.4	3.8	9.2	8.5	2.1	1.8
12	141.4	137.5	4.1	3.2	9.2	8.6	2.1	1.7
13	141.2	136.5	4.3	3.2	9.4	8.7	2.1	1.7
14	141.1	136.7	4.3	3.5	9.1	8.7	2.1	1.6
15	138.3	134.3	4.2	3.1	9.2	8.5	2.1	1.8
16	140.6	136.1	4.2	3.3	9.3	8.8	2.2	1.7
17	141.1	137	4.1	3.5	9.3	8.8	2.1	1.9
18	139.7	135.9	4	3.1	9.3	8.8	2.2	1.8
19	139.3	136	4.5	3.4	9.3	8.8	2	1.5
20	141	136.6	4.4	3.4	9.1	8.4	2.1	1.8
21	138.7	134.7	4.1	3.4	9.3	8.6	2.1	1.6

In this study, diuretic therapy significantly affected serum electrolytes. Tables 7 and 8 show that furosemide produced the largest reductions in sodium (-3.74 mmol/L), potassium (-0.84 mmol/L), calcium (-0.61 mg/dL), and magnesium (-0.36 mg/dL), all statistically significant (p < 0.001). Hydrochlorothiazide caused moderate

declines in sodium (-3.67 mmol/L), potassium (-0.83 mmol/L), calcium (-0.53 mg/dL), and magnesium (-0.33 mg/dL). Spironolactone showed smaller but significant changes, with reductions of sodium (-3.85 mmol/L), potassium (-0.82 mmol/L), calcium (-0.62 mg/dL), and magnesium (-0.37 mg/dL).

Table 7: Comparison of ANOVA for Electrolytes (Na⁺, K⁺, Ca²⁺, Mg²⁺) between Drug Groups

Measure	Group	Mean ± SD (After-Before)	F-Stat	p-value	Conclusion
Na ⁺	Furosemide	-3.74 ± 1.05	0.23	0.7983	Not Significant
Na ⁺	HCTZ	-3.67 ± 0.89			
Na ⁺	Spironolactone	-3.85 ± 0.61			
K ⁺	Furosemide	-0.84 ± 0.21	0.13	0.8740	Not Significant
K ⁺	HCTZ	-0.83 ± 0.21			
K ⁺	Spironolactone	-0.82 ± 0.18			
Ca ²⁺	Furosemide	-0.61 ± 0.12	5.59	0.0046	Significant

Ca ²⁺	HCTZ	-0.53 ± 0.11	1.36	0.2598	Not Significant
Ca ²⁺	Spironolactone	-0.62 ± 0.10			
Mg ²⁺	Furosemide	-0.36 ± 0.09			
Mg ²⁺	HCTZ	-0.33 ± 0.10			
Mg ²⁺	Spironolactone	-0.37 ± 0.11			

Table 8: Paired t-Test for Electrolytes (Before vs After) within Drug Groups

Electrolyte	Group	Baseline Mean ± SD	Post-Intervention Mean ± SD	t-Stat	t-Critical (Two-Tailed)	p-value (Two-Tailed)	Conclusion
Na ⁺	Furosemide	140.03 ± 1.19	136.21 ± 1.40	54.65	1.985	3.93E-74	Significant
Na ⁺	HCTZ	140.24 ± 1.19	136.57 ± 1.44	23.00	2.040	4.82E-21	Significant
Na ⁺	Spironolactone	140.13 ± 1.10	136.29 ± 1.08	28.32	2.086	1.30E-17	Significant
K ⁺	Furosemide	4.25 ± 0.16	3.41 ± 0.26	36.67	1.985	2.90E-58	Significant
K ⁺	HCTZ	4.26 ± 0.14	3.43 ± 0.24	21.35	2.040	4.27E-20	Significant
K ⁺	Spironolactone	4.23 ± 0.16	3.41 ± 0.20	19.22	2.086	2.30E-14	Significant
Ca ²⁺	Furosemide	9.24 ± 0.16	8.64 ± 0.20	47.07	1.985	3.98E-68	Significant
Ca ²⁺	HCTZ	9.22 ± 0.15	8.69 ± 0.20	25.01	2.040	4.10E-22	Significant
Ca ²⁺	Spironolactone	9.21 ± 0.11	8.60 ± 0.13	25.31	2.086	1.16E-16	Significant
Mg ²⁺	Furosemide	2.11 ± 0.07	1.74 ± 0.11	35.08	1.985	1.53E-56	Significant
Mg ²⁺	HCTZ	2.10 ± 0.08	1.77 ± 0.09	15.45	2.040	4.12E-16	Significant
Mg ²⁺	Spironolactone	2.12 ± 0.06	1.75 ± 0.13	13.07	2.086	2.98E-11	Significant

The ANOVA comparison (Table 7) revealed no significant differences between the three drug groups (Furosemide, Hydrochlorothiazide, and Spironolactone) for sodium (Na⁺), potassium (K⁺), and magnesium (Mg²⁺) changes (p > 0.05). However, a significant difference was observed for calcium (Ca²⁺) levels (F = 5.59, p = 0.0046), indicating that diuretic type influenced calcium reduction, with the greatest decrease seen in Spironolactone (-0.62 ± 0.10 mg/dL).

Paired t-test analysis (Table 8) showed that within each drug group, all electrolytes (Na⁺, K⁺, Ca²⁺, Mg²⁺) exhibited statistically significant

reductions from baseline to post-intervention (p < 0.001). Furosemide produced the most pronounced declines across all electrolytes, particularly sodium (-3.82 mmol/L) and magnesium (-0.37 mg/dL), reflecting its potent natriuretic and electrolyte-wasting effects. Hydrochlorothiazide showed moderate but consistent reductions, while Spironolactone, though less potent, still resulted in significant decreases across all electrolytes.

These findings highlight that while all three diuretics cause significant within-group electrolyte depletion, between-group differences were mainly evident for calcium, where the extent

of reduction varied significantly depending on the drug administered.

IV. DISCUSSION

The present research reports that we saw large changes in electrolyte profiles as a result of diuretic therapy which in detail included sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), and magnesium (Mg^{2+}). As reported in Table 2 we noted that out of which hypokalemia (26.5%) took the lead and was followed by hyponatremia (22.4%, also we saw that hypomagnesemia (11.8% and hypocalcemia (8.8% were present which is a repeat of what was reported before that loop and thiazide diuretics are the cause of potassium and sodium loss. Also we noted that in 30.6% of patients there was no imbalance which may be due to inter individual variability and also possibly the result of other concomitant therapies. Also from the ANOVA results in Table 3 we see that there were no significant differences between drug groups for changes in sodium, potassium and magnesium which in turn indicates that all diuretics have a very similar effect on these electrolytes.

The disparity in calcium levels across the groups was notable ($p = 0.0046$), implying that calcium balance can be managed differently depending on the type of diuretic used. This aligns with prior research indicating that thiazide diuretics retain calcium whereas loop diuretics induce calciuresis.

As shown with the paired t-tests in table 4, there were significant increases in Na^+ , K^+ , Ca^{2+} , and Mg^{2+} levels for all diuretic groups pre and post treatment ($p < 0.001$). This further supports the notion that electrolyte deficiency are an invariable result of persistent diuretic therapy. The noted decreases in potassium and magnesium levels are particularly shocking because of the increased risk of hypokalemia and hypomagnesemia, both of which can lead to serious arrhythmic complications. This study emphasizes that despite diuretic therapy deployed for management of hypertension or fluid overload, there is severe electrolyte imbalance that requires constant surveillance.

The data supports prior studies that concentrated on the importance of electrolyte monitoring for patients on sustained diuretics. Moreover, the noted incidence of hypokalemia and hyponatremia strengthens the argument for the potassium-sparing diuretics or other supplementation to counterbalance such risks.

V. CONCLUSION

This study conclusively shows diuretic therapy impacts electrolyte balance, hypokalemia and hyponatremia being the most common issues. All diuretic groups confirmed the depleting effects of sodium, potassium, calcium and magnesium. Important ANOVA results also showcased calcium changes between drug classes. This brings emphasis on individualized monitoring strategies and the need to formulate tailored strategies for close tracking.

Diuretics are paramount for the management of hypertension and cardiovascular diseases, but as these findings emphasize, long-term use leads to electrolyte balance disruption. This teaches us the importance of close monitoring, patient counseling, and therapy modification, including prescription of potassium-sparing diuretics and supplements, to reduce complications. Further research should focus on larger populations with longitudinal follow-up to study the long-term clinical ramifications of managing electrolyte imbalance in diuretic-treated patients.

REFERENCES

- [1]. JJ, C., JGF, C., & AL, C. (2024). Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions— Part II: Combination Therapy. *Current Heart Failure Reports*, 21(2), 115–130. <https://doi.org/10.1007/s11897-024-00644-2>
- [2]. Blebea, N., Pușcașu, C., Ștefănescu, E., & Stăniș, A. M. (2025). Diuretic therapy: mechanisms, clinical applications, and management. *Journal of Mind and Medical Sciences*, 12(1), 26. <https://doi.org/10.3390/jmms12010026>
- [3]. Andersson, N. W., Wohlfahrt, J., Feenstra, B., Hviid, A., Melbye, M., & Lund, M. (2023). Cumulative Incidence of Thiazide-Induced Hyponatremia. *Annals of Internal Medicine*, 177(1), 1–11. <https://doi.org/10.7326/m23-1989>
- [4]. Wu, L., Rodriguez, M., El Hachem, K., & Krittanawong, C. (2024). Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians. *Journal of Clinical Medicine*, 13(15), 4470. <https://doi.org/10.3390/jcm13154470>
- [5]. Nyma, Z., Kitaoka, K., Yano, Y., Kanegae, H., Bayarara, N., Kishi, S., Nagasu, H., Nakano, T., Wada, J., Maruyama, S., Nakagawa, N., Tamura, K., Yokoo, T.,

- Yanagita, M., Narita, I., Yamagata, K., Wada, T., Tsuruya, K., Nakashima, N., . . . Kataoka, H. (2024). Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes. *Scientific Reports*, 14(1). <https://doi.org/10.1038/s41598-024-62152-6>
- [6]. Alam, K., Hayat, A. H., Ullah, A., Sulaiman, S. a. S., Ahmad, W. A., & Ooi, G. S. (2024). The prevalence and impact of clinical pharmacists' intervention on Drug-Related Problems in patients with chronic kidney Disease. *Cureus*. <https://doi.org/10.7759/cureus.59402>
- [7]. Alshogran, O. Y., Hajjar, M. H., Muflih, S. M., & Alzoubi, K. H. (2022). The role of clinical pharmacist in enhancing hemodialysis patients' adherence and clinical outcomes: a randomized-controlled study. *International Journal of Clinical Pharmacy*, 44(5), 1169–1178. <https://doi.org/10.1007/s11096-022-01453-0>
- [8]. Chirnside, J. G., Malone, C. J., Scott, J. G., & Crozier, I. G. (2024). Managing an advanced heart failure patient at home with a Long-Term Continuous Intravenous furosemide infusion. *JACC Case Reports*, 29(19), 102611. <https://doi.org/10.1016/j.jaccas.2024.102611>
- [9]. Calleja, L., Glass, B. D., Cairns, A., & Taylor, S. (2023). Pharmacist-Led Interventions for Medication Adherence in Patients with Chronic Kidney Disease: A Scoping Review. *Pharmacy*, 11(6), 185. <https://doi.org/10.3390/pharmacy11060185>
- [10]. Pradhan, A., Singh, A., Ahuja, R., Sethi, R., & Srivastava, V. (2019). Prevalence and incidence of hyponatremia and their association with diuretic therapy: Results from North India. *Journal of Family Medicine and Primary Care*, 8(12), 3925. https://doi.org/10.4103/jfmpe.jfmpe_604_19
- [11]. Ruiz-Ramos, J., Ramírez, P., Broch, M. J., Gordon, M., Villarreal, E., Pinos, A., Sosa, M., & Castellanos-Ortega, Á. (2018). Vasopressin antagonist efficacy and safety in volume-overloaded critically ill patients: a new therapeutic alternative. *European Journal of Hospital Pharmacy*, 27(3), 157–161. <https://doi.org/10.1136/ejpharm-2018-001664>